vs
ABVC BIOPHARMA, INC.（ABVC）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Bio-Techne的季度营收约是ABVC BIOPHARMA, INC.的371.7倍（$295.9M vs $796.0K）。Bio-Techne净利率更高（12.8% vs -256.6%，领先269.5%）。ABVC BIOPHARMA, INC.同比增速更快（104.5% vs -6.4%）。过去两年ABVC BIOPHARMA, INC.的营收复合增速更高（1041.5% vs 4.2%）
ABVC生物制药是一家处于临床阶段的生物制药企业，专注于开发肿瘤、眼科、中枢神经系统疾病等领域的创新治疗方案，业务覆盖北美及亚洲主要市场，多款自研候选药物正处于临床试验推进阶段。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
ABVC vs TECH — 直观对比
营收规模更大
TECH
是对方的371.7倍
$796.0K
营收增速更快
ABVC
高出110.9%
-6.4%
净利率更高
TECH
高出269.5%
-256.6%
两年增速更快
ABVC
近两年复合增速
4.2%
损益表 — Q3 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $796.0K | $295.9M |
| 净利润 | $-2.0M | $38.0M |
| 毛利率 | 100.0% | 64.6% |
| 营业利润率 | -246.8% | 18.4% |
| 净利率 | -256.6% | 12.8% |
| 营收同比 | 104.5% | -6.4% |
| 净利润同比 | -417.4% | 68.3% |
| 每股收益（稀释后） | $-0.09 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABVCTECH
| Q4 25 | — | $295.9M | ||
| Q3 25 | $796.0K | — | ||
| Q2 25 | — | $317.0M | ||
| Q1 25 | — | $316.2M | ||
| Q4 24 | $2.0K | $297.0M | ||
| Q3 24 | $389.3K | $289.5M | ||
| Q2 24 | $117.1K | $306.1M | ||
| Q1 24 | $1.2K | $303.4M |
净利润ABVCTECH
| Q4 25 | — | $38.0M | ||
| Q3 25 | $-2.0M | — | ||
| Q2 25 | — | $-17.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | $-731.6K | $34.9M | ||
| Q3 24 | $-394.8K | $33.6M | ||
| Q2 24 | $-942.3K | $40.6M | ||
| Q1 24 | $-2.8M | $49.1M |
毛利率ABVCTECH
| Q4 25 | — | 64.6% | ||
| Q3 25 | 100.0% | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | 100.0% | 65.3% | ||
| Q3 24 | 99.9% | 63.2% | ||
| Q2 24 | 99.8% | 66.4% | ||
| Q1 24 | 77.0% | 67.4% |
营业利润率ABVCTECH
| Q4 25 | — | 18.4% | ||
| Q3 25 | -246.8% | — | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | -35837.4% | 16.0% | ||
| Q3 24 | -77.7% | 13.8% | ||
| Q2 24 | -734.2% | 15.0% | ||
| Q1 24 | -235539.8% | 22.1% |
净利率ABVCTECH
| Q4 25 | — | 12.8% | ||
| Q3 25 | -256.6% | — | ||
| Q2 25 | — | -5.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | -37211.3% | 11.7% | ||
| Q3 24 | -101.4% | 11.6% | ||
| Q2 24 | -804.4% | 13.3% | ||
| Q1 24 | -235203.2% | 16.2% |
每股收益（稀释后）ABVCTECH
| Q4 25 | — | $0.24 | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | $-0.02 | $0.22 | ||
| Q3 24 | $-0.03 | $0.21 | ||
| Q2 24 | $-0.08 | $0.26 | ||
| Q1 24 | $-0.29 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $257.2K | $172.9M |
| 总债务越低越好 | — | $260.0M |
| 股东权益账面价值 | $12.1M | $2.0B |
| 总资产 | $21.2M | $2.5B |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ABVCTECH
| Q4 25 | — | $172.9M | ||
| Q3 25 | $257.2K | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | $313.1K | $177.5M | ||
| Q3 24 | $208.2K | $187.5M | ||
| Q2 24 | $200.0K | $152.9M | ||
| Q1 24 | $106.4K | $145.3M |
总债务ABVCTECH
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
股东权益ABVCTECH
| Q4 25 | — | $2.0B | ||
| Q3 25 | $12.1M | — | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | $1.2M | $2.1B | ||
| Q3 24 | $1.6M | $2.1B | ||
| Q2 24 | $1.8M | $2.1B | ||
| Q1 24 | $1.7M | $2.0B |
总资产ABVCTECH
| Q4 25 | — | $2.5B | ||
| Q3 25 | $21.2M | — | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | $7.5M | $2.7B | ||
| Q3 24 | $7.8M | $2.7B | ||
| Q2 24 | $8.0M | $2.7B | ||
| Q1 24 | $8.0M | $2.7B |
负债/权益比ABVCTECH
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-964.7K | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ABVCTECH
| Q4 25 | — | — | ||
| Q3 25 | $-964.7K | — | ||
| Q2 25 | — | $98.2M | ||
| Q1 25 | — | $41.1M | ||
| Q4 24 | $-702.1K | $84.3M | ||
| Q3 24 | $60.2K | $63.9M | ||
| Q2 24 | $-211.4K | $75.5M | ||
| Q1 24 | $-955.8K | $81.0M |
自由现金流ABVCTECH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M | ||
| Q1 24 | — | $64.5M |
自由现金流率ABVCTECH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% | ||
| Q1 24 | — | 21.3% |
资本支出强度ABVCTECH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 5.4% |
现金转化率ABVCTECH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABVC
暂无分部数据
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
